- Highlighted R&D Strategy and Broad Pipeline of 15 Programs including 10 with Worldwide Rights - ATG-010's First Approval in Asia transforms Antengene into a Commercial Entity, 10 Studies in ATG-010 being Conducted in Mainland China - Exciting ATG-008 (mTORC1/2 inhibitor) Signal, ATG-017...
from PR Newswire: https://ift.tt/3DxQEDg
No comments:
Post a Comment